Oral manifestation associated with avelumab
Emerging immunotherapies are becoming more prominent in treating various cancers. However, side effects and toxicities can induce systemic and oral manifestations which can be debilitating and negatively affect a patient’s quality of life. Avelumab is a relatively recent immunotherapy drug that is u...
Saved in:
Main Authors: | Kevin Chung, Annu Singh, Joseph M. Huryn, Cherry L. Estilo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-03-01
|
Series: | Oral Oncology Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906023001383 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Unusual gingival presentation following treatment with pembrolizumab
by: Annu Singh, et al.
Published: (2024-03-01) -
Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01) -
Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01) -
Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01) -
Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)